Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
Molecules ; 25(18)2020 Sep 14.
Article in English | MEDLINE | ID: mdl-32937766

ABSTRACT

To facilitate broad applications and enhance bioactivity, resveratrol was esterified to resveratrol butyrate esters (RBE). Esterification with butyric acid was conducted by the Steglich esterification method at room temperature with N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide (EDC) and 4-dimethyl aminopyridine (DMAP). Our experiments demonstrated the synthesis of RBE through EDC- and DMAP-facilitated esterification was successful and that the FTIR spectra of RBE revealed absorption (1751 cm-1) in the ester region. 13C-NMR spectrum of RBE showed a peak at 171 ppm corresponding to the ester group and peaks between 1700 and 1600 cm-1 in the FTIR spectra. RBE treatment (25 or 50 µM) decreased oleic acid-induced lipid accumulation in HepG2 cells. This effect was stronger than that of resveratrol and mediated through the downregulation of p-ACC and SREBP-2 expression. This is the first study demonstrating RBE could be synthesized by the Steglich method and that resulting RBE could inhibit lipid accumulation in HepG2 cells. These results suggest that RBE could potentially serve as functional food ingredients and supplements for health promotion.


Subject(s)
Butyric Acid/chemical synthesis , Esters/chemical synthesis , Liver/drug effects , Liver/metabolism , Resveratrol/chemical synthesis , Resveratrol/pharmacology , Acetyl-CoA Carboxylase/metabolism , Carbodiimides/chemistry , Cell Culture Techniques , Down-Regulation , Esterification , Hep G2 Cells , Humans , Lipids/chemistry , Magnetic Resonance Spectroscopy , Pyridines/chemistry , Spectroscopy, Fourier Transform Infrared , Sterol Regulatory Element Binding Protein 1/metabolism , Thermogravimetry
2.
J Labelled Comp Radiopharm ; 63(10): 442-455, 2020 08.
Article in English | MEDLINE | ID: mdl-32472945

ABSTRACT

The metabolic alterations in tumors make it possible to visualize the latter by means of positron emission tomography, enabling diagnosis and providing metabolic information. The alanine serine cysteine transporter-2 (ASCT-2) is the main transporter of glutamine and is upregulated in several tumors. Therefore, a good positron emission tracer targeting this transport protein would have substantial value. Hence, the aim of this study is to develop a fluorine-18-labeled version of a V-9302 analogue, one of the most potent inhibitors of ASCT-2. The precursor was labeled with fluorine-18 via a nucleophilic substitution of the corresponding benzylic bromide. The cold reference product was subjected to in vitro assays with [3 H]glutamine in a PC-3 and F98 cell line to determine the affinity for both the human and rat ASCT-2. To evaluate the tracer potential dynamic µPET, images were acquired in a mouse xenograft model for prostate cancer. The tracer could be synthesized with an overall nondecay corrected yield of 3.66 ± 1.90%. in vitro experiments show inhibitor constants Ki of 90 and 125 µM for the PC-3 and F98 cells, respectively. The experiments in the PC-3 xenograft demonstrate a low uptake in the tumor tissue. We have successfully synthesized the radiotracer [18 F]2-amino-4-((2-((3-fluorobenzyl)oxy)benzyl)(2-((3-(fluoromethyl)benzyl)oxy)benzyl)amino)butanoic acid. in vitro experiments show a good affinity for both the human and rat ASCT-2. However, the tracer suffers from poor in vivo tumor uptake in the PC-3 model. Briefly, we present the first fluorine-18-labeled derivative of compound V-9302, a promising novel ASCT-2 blocker used for inhibition of tumor growth.


Subject(s)
Butyric Acid/chemistry , Butyric Acid/chemical synthesis , Positron-Emission Tomography , Animals , Butyric Acid/pharmacology , Cell Line, Tumor , Male , Mice , Rats
3.
Bioresour Technol ; 263: 562-568, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29778795

ABSTRACT

One-pot bioconversion is an economically attractive biorefinery strategy to reduce enzyme consumption. Direct conversion of lignocellulosic biomass for butyric acid production is still challenging because of competition among microorganisms. In a consolidated hydrolysis/fermentation bioprocessing (CBP) the microbial structure may eventually prefer the production of caproic acid rather than butyric acid production. This paper presents a new bioaugmentation approach for high butyric acid production from rice straw. By dosing 0.03 g/L of Clostridium tyrobutyricum ATCC 25755 in the CBP, an increase of 226% higher butyric acid was yielded. The selectivity and concentration also increased to 60.7% and 18.05 g/L, respectively. DNA-sequencing confirmed the shift of bacterial community in the augmented CBP. Butyric acid producer was enriched in the bioaugmented bacterial community and the bacteria related to long chain acids production was degenerated. The findings may be useful in future research and process design to enhance productivity of desired bio-products.


Subject(s)
Butyric Acid/chemical synthesis , Clostridium tyrobutyricum , Oryza/metabolism , Biomass , Fermentation
4.
Int J Biol Macromol ; 108: 1165-1175, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29113890

ABSTRACT

Nowadays, for the industrial implementations, especially in the area of organic synthesis, immobilized enzymes are preferred over their soluble forms. Present study aimed to find fast, cost-efficient, and effective way of lipase immobilization for the use in organic media. Lipase from Aspergillus sp. (Resinase A 2X) was immobilized utilizing cross-linking of enzyme aggregates, covalent immobilization on magnetite particles and adsorption-immobilization using pyrolyzed sugar industry waste product as a novel type of carrier. Covalently- and adsorption-immobilized preparations exhibited greater specific activities (5.61±0.18U/mg and 14.2±0.63U/mg, respectively) in organic reaction media than the soluble form of the enzyme (0.06±0.01U/mg). Enzyme immobilized on the sugar industry waste pyrolyis product was determined as a best way to hyperactivate Resinase A 2X and was chosen for the synthesis of flavor and fragrance compound 2-phenylethyl butanoate. Furthermore, in order to optimize 2-phenylethyl butanoate synthesis conditions, central compositional experimental plan was designed using RSM. It showed that in optimal reaction conditions (4.5h at 40.7°C, with 0.1M of substrate) conversion higher than 90% can be achieved. Studies of the operational stability showed enhanced reusability of adsorption-immobilized lipase (with each cycle, efficiency of the 2-PB synthesis diminished by 20-30%). The use of the sugar industry waste pyrolysis product as a carrier provides a novel, cheap, fast, cost-efficient and eco-friendly way of immobilization with some crucial points to be noted for the best productivity.


Subject(s)
Aspergillus/enzymology , Enzymes, Immobilized/chemistry , Enzymes, Immobilized/metabolism , Lipase/chemistry , Lipase/metabolism , Adsorption , Butyric Acid/chemical synthesis , Butyric Acid/chemistry , Chemistry Techniques, Synthetic , Enzyme Stability , Esterification , Ferrosoferric Oxide/chemistry , Kinetics , Temperature
5.
Molecules ; 21(11)2016 Nov 16.
Article in English | MEDLINE | ID: mdl-27854343

ABSTRACT

In order to systematically explore and understand the structure-activity relationship (SAR) of a lesinurad-based hit (1c) derived from the replacement of the S atom in lesinurad with CH2, 18 compounds (1a-1r) were designed, synthesized and subjected to in vitro URAT1 inhibitory assay. The SAR exploration led to the discovery of a highly potent flexible URAT1 inhibitor, 1q, which was 31-fold more potent than parent lesinurad (IC50 = 0.23 µM against human URAT1 for 1q vs 7.18 µM for lesinurad). The present study discovered a flexible molecular scaffold, as represented by 1q, which might serve as a promising prototype scaffold for further development of potent URAT1 inhibitors, and also demonstrated that the S atom in lesinurad was not indispensable for its URAT1 inhibitory activity.


Subject(s)
Butyric Acid/chemistry , Butyric Acid/pharmacology , Organic Anion Transporters/antagonists & inhibitors , Organic Cation Transport Proteins/antagonists & inhibitors , Butyric Acid/chemical synthesis , Cell Line , Combinatorial Chemistry Techniques , Humans , Inhibitory Concentration 50 , Molecular Structure
6.
Bioresour Technol ; 218: 1208-14, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27474955

ABSTRACT

The aim of this work was to study the butyric acid production from softwood hydrolysate by acetate-consuming Clostridium sp. S1. Results showed that Clostridium sp. S1 produced butyric acid by simultaneously utilizing glucose and mannose in softwood hydrolysate and, more remarkably, it consumed acetic acid in hydrolysate. Clostridium sp. S1 utilized each of glucose, mannose, and xylose as well as mixed sugars simultaneously with partially repressed xylose utilization. When softwood (Japanese larch) hydrolysate containing glucose and mannose as the main sugars was used, Clostridium sp. S1 produced 21.17g/L butyric acid with the yield of 0.47g/g sugar and the selectivity of 1 (g butyric acid/g total acids) owing to the consumption of acetic acid in hydrolysate. The results demonstrate potential of Clostridium sp. S1 to produce butyric acid selectively and effectively from hydrolysate not only by utilizing mixed sugars simultaneously but also by converting acetic acid to butyric acid.


Subject(s)
Butyric Acid/chemical synthesis , Clostridium/metabolism , Wood/chemistry , Wood/microbiology , Acetic Acid/metabolism , Fermentation/physiology , Glucose/metabolism , Mannose/metabolism , Xylose/metabolism
7.
Org Biomol Chem ; 14(25): 5992-6009, 2016 Jul 07.
Article in English | MEDLINE | ID: mdl-27226381

ABSTRACT

A diastereoselective synthesis of (S)-3-(3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid (1), a potential therapeutic agent for the treatment of Idiopathic Pulmonary Fibrosis, which is currently undergoing Phase I clinical trials is reported. The key steps in the synthesis involved alkylation of 2-methylnaphthyridine with (R)-N-Boc-3-(iodomethyl)-pyrrolidine, and an asymmetric Rh-catalysed addition of an arylboronic acid to a 4-(N-pyrrolidinyl)crotonate ester. The overall yield of the seven linear step synthesis was 8% and the product was obtained in >99.5% ee proceeding with 80% de. The absolute configuration of 1 was established by an alternative asymmetric synthesis involving alkylation of an arylacetic acid using Evans oxazolidinone chemistry, acylation using the resulting 2-arylsuccinic acid, and reduction. The absolute configuration of the benzylic asymmetric centre was established as (S).


Subject(s)
Butyric Acid/chemical synthesis , Butyric Acid/pharmacology , Idiopathic Pulmonary Fibrosis/drug therapy , Integrins/antagonists & inhibitors , Pyrrolidines/chemistry , Pyrrolidines/pharmacology , Antigens, Neoplasm , Butyric Acid/chemistry , Butyric Acid/therapeutic use , Chemistry Techniques, Synthetic , Oxidation-Reduction , Pyrrolidines/chemical synthesis , Pyrrolidines/therapeutic use , Stereoisomerism
8.
Eur J Med Chem ; 104: 127-38, 2015 Nov 02.
Article in English | MEDLINE | ID: mdl-26451771

ABSTRACT

The synthesis and antiviral evaluation of a series of dihydropyrimidinone and thiopyrimidine derivatives bearing aryl α,γ-diketobutanoic acid moiety are described using the Biginelli multicomponent reaction as key step. The most active among 20 synthesized novel compounds were 4c, 4d and 5b, which possess nanomolar HIV-1 integrase (IN) stand transfer (ST) inhibition activities. In order to understand their mode of interactions within the IN active site, we docked all the compounds into the previously reported X-ray crystal structure of IN. We observed that compounds 4c, 4d and 5b occupied an area close to the two catalytic Mg(2+) ions surrounded by their chelating triad (E221, D128 and D185), DC16, Y212 and the ß-diketo acid moiety of 4c, 4d and 5b chelating Mg(2+). As those compounds lack anti-HIV activities in cell, their prodrugs were synthetized. The prodrug 4c' exhibited an anti-HIV activity of 0.19 µM in primary human lymphocytes with some cytotoxicity. All together, these results indicate that the new analogs potentially interact within the catalytic site with highly conserved residues important for IN catalytic activity.


Subject(s)
Anti-HIV Agents/pharmacology , Butyric Acid/pharmacology , HIV Integrase Inhibitors/pharmacology , HIV Integrase/metabolism , HIV-1/drug effects , Pyrimidines/pharmacology , Animals , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/chemistry , Butyric Acid/chemical synthesis , Butyric Acid/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Chlorocebus aethiops , Dose-Response Relationship, Drug , HIV Integrase Inhibitors/chemical synthesis , HIV Integrase Inhibitors/chemistry , Humans , Models, Molecular , Molecular Structure , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Structure-Activity Relationship , Vero Cells
9.
Spectrochim Acta A Mol Biomol Spectrosc ; 122: 356-64, 2014 Mar 25.
Article in English | MEDLINE | ID: mdl-24322756

ABSTRACT

Six organotin(IV) carboxylates of the type R2SnL2 [R=CH3 (1), n-C4H9 (2), n-C8H17 (3)] and R3SnL [R=CH3 (4), n-C4H9 (5), C6H5 (6), where L=2-(4-ethoxybenzylidene) butanoic acid, have been synthesized and characterized by elemental analysis, FT-IR and NMR ((1)H, (13)C). The complex (1) was also analyzed by single crystal X-ray analysis. The complexes were screened for antimicrobial, cytotoxic and anti-tumor activities. The results showed significant activity in each area of the activity with few exceptions. DNA interactions studies of ligand HL and representative complex 2 were investigated by UV-Visible absorption spectroscopy and viscosity measurements. The results showed that both ligand HL and complex 2 interact with SS-DNA via intercalation as well as minor groove binding.


Subject(s)
Benzylidene Compounds/chemical synthesis , Benzylidene Compounds/metabolism , Butyrates/chemical synthesis , Butyrates/metabolism , Butyric Acid/chemical synthesis , Butyric Acid/metabolism , DNA/metabolism , Organotin Compounds/chemical synthesis , Organotin Compounds/metabolism , Animals , Anti-Infective Agents/chemistry , Anti-Infective Agents/pharmacology , Antifungal Agents/pharmacology , Antineoplastic Agents/pharmacology , Artemia/drug effects , Bacteria/drug effects , Benzylidene Compounds/chemistry , Benzylidene Compounds/toxicity , Butyrates/chemistry , Butyrates/toxicity , Butyric Acid/chemistry , Butyric Acid/toxicity , Cell Death/drug effects , Crystallography, X-Ray , Fishes , Fungi/drug effects , Ligands , Magnetic Resonance Spectroscopy , Male , Microbial Sensitivity Tests , Organotin Compounds/chemistry , Organotin Compounds/toxicity , Plant Tumors , Spectroscopy, Fourier Transform Infrared , Viscosity/drug effects
10.
Artif Cells Nanomed Biotechnol ; 41(5): 339-43, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23305408

ABSTRACT

In this study, the production of ethyl butyrate was investigated by using immobilized lipase enzyme in shake flasks. In order to determine optimum conditions for the production, response surface methodology was used. The model indicated the optimum conditions for maximum conversion (9.1%) at the 0.31 M substrate concentration, acid- alcohol molar ratio of 0.49, immobilized enzyme 25% (w/v) at 35°C, for 3 hours which were in good agreement with the experimental value. At the end of the 55 hours conversion was obtained as 61.3%. When Na2HPO4 was used in reaction medium conversion increased to 90.3% for 55 hours.


Subject(s)
Butyrates/chemical synthesis , Butyric Acid/chemical synthesis , Ethanol/chemical synthesis , Analysis of Variance , Enzymes, Immobilized/metabolism , Humans , Lipase/metabolism , Models, Statistical
11.
Chem Commun (Camb) ; 48(34): 4124-6, 2012 Apr 28.
Article in English | MEDLINE | ID: mdl-22430371

ABSTRACT

Organic base-catalyzed reaction of (S)-N-tert-butanesulfinyl (3,3,3)-trifluoroacetaldimine with dialkyl malonates was found to be effective for synthesis of both (S,S(S)) and (R,S(S)) ß-aminomalonates in high yield with good to excellent diastereoselectivity (76-98% de). The products of this Mannich reaction provide direct access to ß-trifluoromethyl-ß-alanine of either (R) or (S) absolute configuration.


Subject(s)
Amines/chemistry , Butyric Acid/chemistry , Amines/chemical synthesis , Butyric Acid/chemical synthesis , Catalysis , Halogenation , Stereoisomerism
12.
Nucl Med Biol ; 39(5): 687-96, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22336374

ABSTRACT

INTRODUCTION: The small molecule 2-(5-(dimethylamino)naphthalene-1-sulfonamido)-2-(fluoromethyl)butanoic acid (NST732) is a member of the ApoSense family of compounds, capable of selective targeting, binding and accumulation within cells undergoing apoptotic cell death. It has application in molecular imaging and blood clotting particularly for monitoring antiapoptotic drug treatments. We are investigating a fluorine-18-radiolabeled analog of this compound for positron emission tomography studies. METHODS: We prepared the tosylate precursor methyl 2-(5-(dimethylamino)naphthalene-1-sulfonamido)-2-(tosyloxymethyl)butanoate (4) to synthesize fluorine-18-labeled NST732. Fluorination reaction of the tosylate precursor in 1:1 acetonitrile:dimethylsulfoxide with tetrabutyl ammonium fluoride proceeds through an aziridine intermediate (4A) to afford two regioisomers: 2-(5-(dimethylamino)naphthalene-1-sulfonamido)-2-fluorobutanoate (5) and methyl 2-(5-(dimethylamino)naphthalene-1-sulfonamido)-2-(fluoromethyl)butanoate (6). Acid hydrolysis of the fluoromethylbutanoate (6) isomer produced NST732. As the fluorination reaction of the tosylate precursor proceeds through an aziridine intermediate (4A) and the fluorination conceivably could be done directly on the aziridine, we have separately prepared an aziridine precursor (4A). Fluorine-18 labeling of the aziridine precursor (4A) was performed with [(18)F]tetrabutyl ammonium fluoride to afford the same two regioisomers (5 and 6). The [18F]2-((5-dimethylamino)naphthalene-1-sulfonamido)methyl)-2-fluorobutanoic acid (NST732) was then obtained by the hydrolysis of corresponding [18F]-labeled ester (6) with 6 N hydrochloric acid. RESULTS: Two regioisomers obtained from the fluorination reaction of aziridine were easily separated by high-performance liquid chromatography. The total radiochemical yield was 15%±3% (uncorrected, n=18) from the aziridine precursor in a 70-min synthesis time with a radiochemical purity>99%. CONCLUSION: Fluorine-18-labeled ApoSense compound [18F]NST732 is prepared in moderate yield by direct fluorination of an aziridine precursor.


Subject(s)
Aminobutyrates/chemistry , Aminobutyrates/chemical synthesis , Aziridines/chemistry , Butyric Acid/chemistry , Butyric Acid/chemical synthesis , Chemistry Techniques, Synthetic/methods , Sulfonamides/chemistry , Sulfonamides/chemical synthesis , Chemistry Techniques, Synthetic/standards , Radiochemistry , Reference Standards
13.
J Med Chem ; 52(14): 4443-53, 2009 Jul 23.
Article in English | MEDLINE | ID: mdl-19530681

ABSTRACT

A series of 3-acylindole-1-benzylcarboxylic acids were designed and synthesized while searching for a PPARgamma modulator with additional moderate intrinsic PPARalpha agonistic activity. 2-[3-[[3-(4-Chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-(2R)-butanoic acid (12d) was identified as such an agent which demonstrated potent efficacy in lowering both glucose and lipids in multiple animal models with significantly attenuated side effects such as fluid retention and heart weight gain associated with PPARgamma full agonists. The moderate PPARalpha activity of 12d not only contributed to the agent's ability to manage lipid profiles but also appears to have potentiated its PPARgamma efficacy in lowering glucose levels in preclinical diabetic animal models.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Drug Discovery , Dyslipidemias/drug therapy , PPAR gamma/agonists , PPAR gamma/metabolism , Animals , Blood Glucose/metabolism , Butyric Acid/chemical synthesis , Butyric Acid/chemistry , Butyric Acid/pharmacology , Butyric Acid/therapeutic use , Cell Line , Cholesterol/blood , Cricetinae , Diabetes Mellitus, Type 2/blood , Dogs , Dyslipidemias/blood , Female , Humans , Indoles/chemistry , Male , Mice , Rats , Structure-Activity Relationship
14.
Bioorg Med Chem Lett ; 19(2): 502-7, 2009 Jan 15.
Article in English | MEDLINE | ID: mdl-19041242

ABSTRACT

The involvement of mu-calpain in neurological disorders, such as stroke and Alzheimer's disease has attracted considerable interest in the use of calpain inhibitors as therapeutic agents. 4-Aryl-4-oxobutanoic acid amide derivatives 4 were designed as acyclic variants of mu-calpain inhibitory chromone and quinolinone derivatives. Of the compounds synthesized, 4c-2, which possesses a 2-methoxymethoxy group at the phenyl ring and a primary amide at the warhead region most potently inhibited mu-calpain (IC(50)=0.34 microM). Our findings suggest that the 4-aryl-4-oxobutanoic acid amide derivatives should be considered as a new family of mu-calpain inhibitors.


Subject(s)
Butyric Acid/chemistry , Butyric Acid/pharmacology , Calpain/antagonists & inhibitors , Cysteine Proteinase Inhibitors/chemistry , Cysteine Proteinase Inhibitors/pharmacology , Amides/chemistry , Butyric Acid/chemical synthesis , Cysteine Proteinase Inhibitors/chemical synthesis , Drug Design
15.
J Pept Res ; 64(2): 43-50, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15251030

ABSTRACT

Hofmann rearrangement of Nalpha-Boc-L-Gln-OH mediated by a polymer-supported hypervalent iodine reagent poly[(4-diacetoxyiodo)styrene] (PSDIB) in water afforded Nalpha-Boc-L-alpha,gamma-diaminobutyric acid (Boc-Dab-OH, 1) in 87% yield. Nalpha-Z-derivative (Z-Dab-OH, 2) was prepared with PSDIB in 83% yield. Since the reaction of Nalpha-Fmoc-Gln-OH by this procedure did not proceed because of the insolubility of Fmoc-Gln-OH in aqueous media, we synthesized Fmoc-Dab(Boc)-OH (5) from 2 in 54% yield. Polymyxin B heptapeptide (PMBH) which contains four Dab residues was successfully synthesized in a solution-phase synthesis.


Subject(s)
Amino Acids , Butyric Acid , Iodine/chemistry , Polymers , Polymyxin B/analogs & derivatives , Water/chemistry , Amino Acids/chemical synthesis , Amino Acids/chemistry , Butyric Acid/chemical synthesis , Butyric Acid/chemistry , Molecular Structure , Peptides/chemical synthesis , Peptides/chemistry , Polymyxin B/chemistry , Solvents
16.
Chem Phys Lipids ; 126(1): 49-53, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14580710

ABSTRACT

(Z)-tetracos-5-enoic acid and racemic cis-4-(2-octadecylcyclopropane-1-yl)-butanoic acid have been prepared from 1-eicosene by a new facile route. Periodic acid cleavage of the epoxide of 1-eicosene gave nonadecanal which was condensed with 4-carboxybutyltriphenylphosphonium bromide to give predominately (Z)-tetracos-5-enoic acid. Simmons-Smith type cyclopropanation of (Z)-tetracos-5-enoic acid gave a minor proportion of racemic cis-4-(2-octadecylcyclopropane-1-yl)-butanoic acid accompanied by major amounts of its methyl ester.


Subject(s)
Butyrates/chemical synthesis , Butyric Acid/chemical synthesis , Fatty Acids, Monounsaturated/chemical synthesis , Bacteria/chemistry , Bacteria/ultrastructure , Cell Wall/chemistry , Stereoisomerism
SELECTION OF CITATIONS
SEARCH DETAIL
...